Drug Profile


Alternative Names: AGN-203818; AGN-XX/YY

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ACADIA Pharmaceuticals; Allergan
  • Developer Allergan
  • Class Analgesics; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic neuropathies; Fibromyalgia; Pain

Most Recent Events

  • 29 Mar 2012 Rezatomidine is still in phase II development for Pain in USA and Europe
  • 19 Jan 2012 Allergan terminates a phase II trial for fibromyalgia syndrome pain in the US (NCT00445705)
  • 19 Jan 2012 Allergan terminates a phase II trial for irritable bowel syndrome pain in the US (NCT00441766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top